The Effect of Cisapride Combined with Hemoperfusion on Gastrointestinal Symptoms and Gastrointestinal Hormone Levels in CRF Maintenance Hemodialysis Patients
Abstract：【Objective】To explore the effects of cisapride assisted blood perfusion therapy on gastrointestinal symptoms and gastrointestinal hormone levels in maintenance hemodialysis patients with chronic renal failure (CRF).【Methods】A retrospective analysis was conducted on the clinical data of 72 patients with CRF admitted to our hospital from February 2021 to January 2023. According to the treatment method, they were divided into an observation group and a control group, with 36 cases in each group. Both groups received maintenance hemodialysis treatment, the control group received hemoperfusion treatment, and the observation group received cisapride treatment on the basis of the control group. After 2 weeks of treatment, renal function (Scr), urea nitrogen (BUN), glomerular filtration rate (GFR), gastrointestinal symptoms, gastrointestinal hormones [somatostatin (SS), motilin (MOT), vasoactive intestinal peptide (VIP)], serum fibroblast growth factor 23 (FGF-23), calcitonin gene related peptide (CGRP), tumor necrosis factor alpha (TNF-α) levels, and incidence of adverse reactions were compared between the two groups.【Results】After treatment, Scr and BUN of two groups decreased compared to before treatment, EGER increased compared to that before treatment (P<0.05); There was no statistically significant difference between Scr,BUN and eGER in the two sets (P>0.05). After treatment, the scores of acid reflux, nausea and vomiting, bloating, belching, and constipation in both groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).After treatment, The level of serum MOT and SS in the observation group was lower than that before treatment and that in the control group, VIP was higher than that before treatment and that in the control group (P<0.05). After treatment, The levels of serum FGF-23 CGRP and TNF-α in two groups were lower than those before treatment, and the observation group was lower than the control group (P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P<0.05).【Conclusion】Cisapride assisted hemoperfusion therapy for CRF maintenance hemodialysis can regulate gastrointestinal hormone levels, improve gastrointestinal symptoms, alleviate inflammatory damage, and has high safety.
王东南, 杨静, 贾转曌. 西沙必利联合血液灌流对CRF维持性血液透析患者胃肠道症状及胃肠激素水平的影响[J]. 医学临床研究, 2024, 41(5): 732-735.
WANG Dongnan, YANG Jing, JIA Zhuanzhao. The Effect of Cisapride Combined with Hemoperfusion on Gastrointestinal Symptoms and Gastrointestinal Hormone Levels in CRF Maintenance Hemodialysis Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 732-735.
2024, Vol. 41 
